TNFAIP3-interacting protein 1 (TNIP1)

TNFAIP3-interacting protein 1 (TNIP1), also known as ABIN-1, is a ubiquitin-binding adaptor protein that regulates multiple forms of programmed cell death (apoptosis, necroptosis, pyroptosis) and is a critical negative regulator of inflammation. It does this largely by inhibiting nuclear factor kappa-B (NF-κB) activation and modulating related signaling pathways, including those triggered by TNF, Toll-like receptors (TLR), and pattern recognition receptors[1][3][4][6][7]. TNIP1 collaborates with A20 (TNFAIP3), a well-established anti-inflammatory molecule, by binding to ubiquitinated signaling intermediates to terminate inflammatory signaling[3][4][7]. Its roles extend to regulation of mitophagy and selective autophagy, suppression of type I interferon production, and maintenance of immune and tissue homeostasis[6]. Mutations or SNPs in TNIP1 are strongly associated with increased susceptibility to autoimmune and chronic inflammatory diseases such as systemic lupus erythematosus, psoriatic arthritis, and rheumatoid arthritis[4][3][6]. TNIP1 is also important in cellular response to infection, such as acting as a host factor in HIV-1 virion biology[4]. It is an intrinsically disordered protein, allowing it to interact flexibly with diverse signaling proteins and complexes[2]. Given its central regulatory function in cell death and inflammation, TNIP1 is considered a promising candidate for therapeutic modulation to treat refractory inflammatory disorders, though there are no marketed drugs currently acting directly on TNIP1[1][4][6].

Other names

ABIN-1KIAA0113NAF1VANNef-associated factor 1HIV-1 Nef-interacting proteinNip40-1Virion-associated nuclear shuttling proteinA20-binding inhibitor of NF-kappa-B activation 1Nef-associated factor 1 SNPhVAN

Not applicable (no direct drug interaction established); Inhibits NF-kappa-B and type I interferon signaling by protein–protein interactions; represses Toll-like receptor and TNF receptor-mediated cell death pathways